BRÈVE

sur Adolore Biotherapeutics, Inc.

Adolore BioTherapeutics Unveils Strategy for Non-Opioid Analgesic Gene Therapies

Adolore BioTherapeutics, a biotechnology company, has announced significant progress in its pipeline for opioid-free gene therapy treatments targeting chronic pain. The company’s development program for osteoarthritis (OA) knee pain is fully funded through initial clinical studies by a NIH/NINDS HEAL program grant.

Adolore is advancing two preclinical programs: ADB-101 for erythromelalgia and ADB-102 for knee OA. The company's approach utilizes CA8* gene therapy, a novel non-opioid, analgesic protein, and a bio-engineered HSV-derived vector for efficient delivery to sensory neurons.

Plans to present data at scientific congresses and publish in leading journals are in place for 2024. The company is scaling up its manufacturing process and expects to produce its initial GMP batch by 2025. Recent achievements include the issuance of a U.S. patent for CA8* gene therapy.

Financially, Adolore has raised $2.5 million in convertible debt, projected to sustain operations through mid-2026.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Adolore Biotherapeutics, Inc.